SCHEMBL2912557

SCHEMBL2912557

COc1ccc2cnc(Nc3cc(C)c4cn[nH]c4c3)nc2c1C

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 2/20 0.45
CDK4 P11802 6/20 0.43
CCND1 P24385 6/20 0.43
CCNE1 P24864 4/20 0.43
CDK2 P24941 4/20 0.43
CDK1 P06493 3/20 0.43
CCNB1 P14635 3/20 0.43
PDGFRB P09619 4/20 0.42
PDGFRA P16234 4/20 0.42
JAK2 O60674 3/20 0.40
JAK1 P23458 3/20 0.40
JAK3 P52333 3/20 0.40
CYP3A4 P08684 2/20 0.40
TYK2 P29597 1/20 0.40
CYP1A2 P05177 1/20 0.40
KDR P35968 2/20 0.40
RET P07949 1/20 0.40
AGPAT2 O15120 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.38
RAF1 P04049 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2919831 0.90 IGF1R (0.43) IGF1RCDK4CCND1CCNE1CDK2
SCHEMBL2917777 0.86 IGF1R (0.57) IGF1RPDGFRBPDGFRAKDRRET
SCHEMBL2920288 0.85 PDGFRB (0.37) IGF1RCDK4CCND1CCNE1CDK2
SCHEMBL2916270 0.85 CDK4 (0.41) IGF1RCDK4CCND1CCNE1CDK2
SCHEMBL2919211 0.85 CDC7 (0.41) IGF1RPDGFRBPDGFRAKDR
SCHEMBL2918438 0.83 IGF1R (0.46) IGF1RCDK4CCND1CCNE1CDK2
SCHEMBL13175217 0.82 PDGFRB (0.36) IGF1RCCNE1CDK2PDGFRBPDGFRA
SCHEMBL2913576 0.82 EGFR (0.40) IGF1RPDGFRBPDGFRAJAK2JAK1
SCHEMBL2917081 0.81 SYK (0.41) PDGFRBPDGFRAJAK2JAK1JAK3
SCHEMBL2916874 0.81 CDK4 (0.43) IGF1RCDK4CCND1CCNE1CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100311965-A1 2-AMINOQUINAZOLINE DERIVATIVE CARNA BIOSCIENCES INC. (JP) 2010-12-09 US disclosed
US-20100311965-A1 2-AMINOQUINAZOLINE DERIVATIVE CARNA BIOSCIENCES INC. (JP) 2010-12-09 US disclosed
US-20100311965-A1 2-AMINOQUINAZOLINE DERIVATIVE CARNA BIOSCIENCES INC. (JP) 2010-12-09 US disclosed
EP-2226315-A1 2-AMINOQUINAZOLINE DERIVATIVE Carna Biosciences Inc. (JP) 2010-09-08 EP disclosed
EP-2226315-A1 2-AMINOQUINAZOLINE DERIVATIVE Carna Biosciences Inc. (JP) 2010-09-08 EP disclosed
WO-2009084695-A1 2-AMINOQUINAZOLINE DERIVATIVE CARNA BIOSCIENCES INC. (JP) 2009-07-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100311965-A1 2-AMINOQUINAZOLINE DERIVATIVE DSTYK, ABL1, EEF2K IGF1R 659/4885CDK4 218/4885CCND1 1388/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.